Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Director Joshua S. Boger sold 6,500 shares of the business’s stock in a transaction dated Wednesday, September 28th. The shares were sold at an average price of $88.15, for a total transaction of $572,975.00. Following the completion of the transaction, the director now owns 274,725 shares in the company, valued at $24,217,008.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) opened at 87.21 on Friday. The stock’s market capitalization is $21.61 billion. Vertex Pharmaceuticals Inc. has a 52-week low of $75.90 and a 52-week high of $134.71. The stock has a 50 day moving average of $94.79 and a 200 day moving average of $89.64.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Wednesday, July 27th. The pharmaceutical company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.03. The business had revenue of $431.61 million for the quarter, compared to analysts’ expectations of $428.08 million. Vertex Pharmaceuticals had a negative net margin of 17.77% and a negative return on equity of 12.34%. The business’s revenue was up 159.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.54) EPS. Analysts forecast that Vertex Pharmaceuticals Inc. will post $0.93 earnings per share for the current year.
Several large investors have recently modified their holdings of VRTX. Commonwealth Equity Services Inc raised its position in shares of Vertex Pharmaceuticals by 23.7% in the first quarter. Commonwealth Equity Services Inc now owns 6,999 shares of the pharmaceutical company’s stock worth $556,000 after buying an additional 1,342 shares during the period. Virginia Retirement System acquired a new position in shares of Vertex Pharmaceuticals during the first quarter worth about $317,000. Pacad Investment Ltd. acquired a new position in shares of Vertex Pharmaceuticals during the first quarter worth about $715,000. Ngam Advisors L.P. raised its position in shares of Vertex Pharmaceuticals by 28.5% in the first quarter. Ngam Advisors L.P. now owns 64,855 shares of the pharmaceutical company’s stock worth $5,155,000 after buying an additional 14,372 shares during the period. Finally, Prudential Financial Inc. raised its position in shares of Vertex Pharmaceuticals by 59.9% in the first quarter. Prudential Financial Inc. now owns 496,217 shares of the pharmaceutical company’s stock worth $39,445,000 after buying an additional 185,800 shares during the period. 96.19% of the stock is currently owned by institutional investors and hedge funds.
VRTX has been the topic of a number of research analyst reports. Vetr upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $94.38 target price on the stock in a research note on Monday, June 13th. Zacks Investment Research upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $98.00 price target on the stock in a research note on Wednesday, July 20th. Piper Jaffray Cos. restated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Saturday, June 18th. Jefferies Group restated a “buy” rating and set a $103.00 price target on shares of Vertex Pharmaceuticals in a research note on Friday, June 17th. Finally, Credit Suisse Group AG restated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, June 16th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $117.60.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.